Current Report Filing (8-k)
November 23 2018 - 1:44PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
November 18, 2018
Northwest Biotherapeutics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction
of incorporation)
|
001-35737
(Commission
File Number)
|
94-3306718
(IRS Employer
Identification No.)
|
4800 Montgomery Lane, Suite 800
Bethesda, Maryland 20814
(Address of Principal Executive Offices)
(240) 497-9024
(Registrant’s telephone number, including
area code)
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
Growth Company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
|
On November 18, 2018, the disinterested members of Northwest Biotherapeutics, Inc.’s (the “Company”)
Board of Directors (the “Board”) approved an increase of the equity compensation option pool to reflect increases in
the numbers of issued and outstanding shares since the prior equity awards were made. This incremental increase in options brings
the pool to approximately twenty percent of 516,311,311 outstanding shares of common stock. The incremental options are being issued
in individual awards which are in the process of being implemented in individual agreements, including with respect to certain
conditions such as vesting over 4 years, subject to potential acceleration events, and, in the case of the independent directors,
shareholder approval of the awards. The exercise price of the options will be $0.25, in accordance with the prior trading day’s
closing price, and the exercise period will be 10 years. In approving the incremental increase, the Board took account of a number
of factors, including the fact that, while the Company was listed on Nasdaq, the shareholders approved an equity compensation plan
under which the aggregate equity compensation was to be maintained at twenty percent of the issued and outstanding shares of the
Company on an evergreen basis.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NORTHWEST BIOTHERAPEUTICS, INC.
|
|
|
|
|
Date: November 23, 2018
|
By:
/s/ Linda Powers
|
|
Name: Linda Powers
|
|
Title: Title: Chief Executive Officer
and Chairman
|
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Sep 2023 to Sep 2024